BR112012000862A8 - composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento - Google Patents
composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamentoInfo
- Publication number
- BR112012000862A8 BR112012000862A8 BR112012000862A BR112012000862A BR112012000862A8 BR 112012000862 A8 BR112012000862 A8 BR 112012000862A8 BR 112012000862 A BR112012000862 A BR 112012000862A BR 112012000862 A BR112012000862 A BR 112012000862A BR 112012000862 A8 BR112012000862 A8 BR 112012000862A8
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- individual
- condition
- need
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22606009P | 2009-07-16 | 2009-07-16 | |
US29009509P | 2009-12-24 | 2009-12-24 | |
PCT/US2010/042253 WO2011009039A2 (en) | 2009-07-16 | 2010-07-16 | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112012000862A2 BR112012000862A2 (pt) | 2017-10-31 |
BR112012000862A8 true BR112012000862A8 (pt) | 2018-01-09 |
Family
ID=43450234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012000862A BR112012000862A8 (pt) | 2009-07-16 | 2010-07-16 | composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento |
Country Status (12)
Country | Link |
---|---|
US (4) | US8258186B2 (pt) |
EP (2) | EP3473247A1 (pt) |
JP (4) | JP6112449B2 (pt) |
CN (2) | CN104997762B (pt) |
AU (2) | AU2010273277B2 (pt) |
BR (1) | BR112012000862A8 (pt) |
CA (1) | CA2768018C (pt) |
DK (1) | DK2453886T3 (pt) |
ES (1) | ES2715173T3 (pt) |
HK (1) | HK1176548A1 (pt) |
NZ (3) | NZ628513A (pt) |
WO (1) | WO2011009039A2 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2121586T3 (en) | 2007-03-09 | 2017-06-19 | Pathologica Llc | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS |
DK2453886T3 (en) | 2009-07-16 | 2019-03-25 | Pathologica Llc | ORGANIC ADMINISTRATION COMPREHENSIVE MGBG AND DISEASE METHODS |
US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
NO2665471T3 (pt) | 2011-01-19 | 2018-05-26 | ||
WO2013083813A2 (en) * | 2011-12-07 | 2013-06-13 | Universität Zürich | Modulators of spermine/spermidine n'-acetyltransferase (ssat) and ssat associated proteins for use in prevention or treatment of rheumatoid arthritis |
US20140107218A1 (en) * | 2012-10-15 | 2014-04-17 | Nestec Sa | Methods for maintaining eye health and ameliorating opthalmic maladies in animals |
US10085955B2 (en) | 2013-01-08 | 2018-10-02 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
DK3785706T3 (da) | 2016-03-25 | 2023-09-11 | Aminex Therapeutics Inc | Biotilgængelige polyaminer |
WO2018027149A1 (en) * | 2016-08-04 | 2018-02-08 | University Of Miami | Methods of treating alport syndrome |
JP6840386B2 (ja) * | 2017-04-26 | 2021-03-10 | 学校法人 関西大学 | 細胞足場材料製造用組成物ならびに細胞足場材料およびその製造方法 |
US11865095B2 (en) | 2020-09-30 | 2024-01-09 | Aminex Therapeutics, Inc. | Combination drug substance of polyamine transport inhibitor and DFMO |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4201788A (en) * | 1976-10-20 | 1980-05-06 | University Patents, Inc. | Process for alleviating proliferative skin diseases |
US5614557A (en) * | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
US5580715A (en) | 1994-08-05 | 1996-12-03 | The Regents Of The University Of California | Diagnosis of cancer having clonal macrophage involvement |
US5698563A (en) | 1995-01-13 | 1997-12-16 | Alteon Inc. | Bis- hydrazones! |
AU733866B2 (en) | 1996-09-13 | 2001-05-31 | University Of Florida Research Foundation, Inc. | Method of inhibiting biosynthesis of EIf5A |
AR009380A1 (es) | 1996-10-21 | 2000-04-12 | Sumitomo Chemical Co | Proceso de preparacion de un derivado de piridazin-3-ona, util como herbicida, acido carboxilico de utilizacion en el mismo, sal de este ultimo y proceso para preparar dicho acido carboxilico |
US6083496A (en) | 1996-10-22 | 2000-07-04 | Universite Laval | Polyamine transport inhibitors |
WO1999003823A2 (en) | 1997-07-15 | 1999-01-28 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
US5889061A (en) | 1997-10-15 | 1999-03-30 | Wisconsin Alumni Research Foundation | Conformationally restricted polyamines |
US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
US8198334B2 (en) | 1997-10-27 | 2012-06-12 | Pathologica Llc | Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
US6169115B1 (en) * | 1998-05-22 | 2001-01-02 | Rima Kaddurah-Daouk | Use of aminoguanidine analogs for the treatment of diseases of the nervous system |
EP1177197B1 (en) | 1999-04-30 | 2006-08-09 | Cellgate, Inc. | Polyamines and their use in therapy |
US6544541B1 (en) | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
AU2002235126A1 (en) | 2000-11-08 | 2002-05-21 | Slil Biomedical Corporation | Novel polyamine analog-amino acid conjugates useful as anticancer agents |
US7754765B2 (en) | 2000-12-01 | 2010-07-13 | Radical Vision Therapeutics Inc | Copper chelators for treating ocular inflammation |
JP4253503B2 (ja) | 2001-01-08 | 2009-04-15 | メディクエスト セラピューティックス インク | 疎水性ポリアミン類似体及びそれらの使用方法 |
US7045550B2 (en) | 2001-08-07 | 2006-05-16 | Wisconsin Alumni Research Foundation | Polyamines and analogs for protecting cells during cancer chemotherapy and radiotherapy |
WO2003016491A2 (en) | 2001-08-15 | 2003-02-27 | The Regents Of The University Of California | Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
JP2005510524A (ja) | 2001-11-16 | 2005-04-21 | アルス・セラピー・デベロツプメント・フアンデーシヨン・インコーポレーテツド | ポリアミン経路の調節による神経変性障害の治療 |
US7622117B2 (en) | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
EP1613263A4 (en) | 2003-01-31 | 2007-11-28 | Pathologica Llc | MONITORING AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS |
US20050025825A1 (en) | 2003-07-31 | 2005-02-03 | Xanodyne Pharmacal, Inc. | Tranexamic acid formulations with reduced adverse effects |
WO2005041988A1 (en) | 2003-10-22 | 2005-05-12 | University Of Florida | Method and composition for pain amelioration |
WO2005105729A1 (en) | 2004-02-13 | 2005-11-10 | Mediquest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
WO2005107801A2 (en) | 2004-04-29 | 2005-11-17 | The Regents Of The University Of Colorado | Systems and methods for treating human inflammatory and proliferative diseases, with a combination of fatty acid metabolism inhibitors and glycolytic inhibitors and/or ucp and/or fas antibodies |
AU2006275679B2 (en) | 2005-07-29 | 2012-04-12 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of Chk2 kinase inhibitors for cancer treatment |
EP1937235B1 (en) | 2005-09-23 | 2015-07-01 | Pathologica, LLC. | Methods for treating viral infections using polyamine analogs |
WO2007040535A1 (en) | 2005-10-03 | 2007-04-12 | Cellgate, Inc. | Use of polyamine analogs for treatment and prevention of intestinal polyps |
CN101511921A (zh) * | 2006-07-28 | 2009-08-19 | 埃克阿泰克有限责任公司 | 具有聚氨酯底漆的车窗面板 |
US20110091418A1 (en) | 2006-09-25 | 2011-04-21 | Pathlogica, LLC | Methods for treating viral infections using polyamine analogs |
DK2121586T3 (en) | 2007-03-09 | 2017-06-19 | Pathologica Llc | MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS |
WO2008112251A1 (en) | 2007-03-14 | 2008-09-18 | Progen Pharmaceuticals, Inc. | Cyclopropyl-containing polyamine analogs as disease therapies |
WO2009018368A1 (en) * | 2007-07-30 | 2009-02-05 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders |
DK2453886T3 (en) | 2009-07-16 | 2019-03-25 | Pathologica Llc | ORGANIC ADMINISTRATION COMPREHENSIVE MGBG AND DISEASE METHODS |
US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
EP2283830A1 (en) | 2009-07-23 | 2011-02-16 | Actogenix N.V. | Aqueous enteric capsule coating |
NO2665471T3 (pt) | 2011-01-19 | 2018-05-26 | ||
US10085955B2 (en) | 2013-01-08 | 2018-10-02 | Pathologica Llc | Methods and compositions for treatment of demyelinating diseases |
-
2010
- 2010-07-16 DK DK10800602.4T patent/DK2453886T3/en active
- 2010-07-16 CN CN201510274080.4A patent/CN104997762B/zh not_active Expired - Fee Related
- 2010-07-16 NZ NZ628513A patent/NZ628513A/en not_active IP Right Cessation
- 2010-07-16 CA CA2768018A patent/CA2768018C/en active Active
- 2010-07-16 WO PCT/US2010/042253 patent/WO2011009039A2/en active Application Filing
- 2010-07-16 ES ES10800602T patent/ES2715173T3/es active Active
- 2010-07-16 US US12/837,753 patent/US8258186B2/en active Active
- 2010-07-16 BR BR112012000862A patent/BR112012000862A8/pt not_active Application Discontinuation
- 2010-07-16 EP EP18210165.9A patent/EP3473247A1/en not_active Ceased
- 2010-07-16 CN CN201080041853.XA patent/CN102686222B/zh active Active
- 2010-07-16 NZ NZ597488A patent/NZ597488A/en not_active IP Right Cessation
- 2010-07-16 AU AU2010273277A patent/AU2010273277B2/en not_active Ceased
- 2010-07-16 NZ NZ715686A patent/NZ715686A/en not_active IP Right Cessation
- 2010-07-16 JP JP2012520810A patent/JP6112449B2/ja active Active
- 2010-07-16 EP EP10800602.4A patent/EP2453886B1/en active Active
-
2012
- 2012-07-24 US US13/556,948 patent/US8609734B2/en active Active
-
2013
- 2013-03-18 HK HK13103363.8A patent/HK1176548A1/xx not_active IP Right Cessation
- 2013-10-25 US US14/063,541 patent/US9616035B2/en active Active
-
2015
- 2015-09-11 JP JP2015180110A patent/JP2016065045A/ja active Pending
-
2016
- 2016-12-01 AU AU2016266049A patent/AU2016266049B2/en not_active Ceased
-
2017
- 2017-02-23 US US15/441,122 patent/US20170290788A1/en not_active Abandoned
-
2018
- 2018-03-06 JP JP2018040226A patent/JP6883930B2/ja active Active
-
2019
- 2019-11-26 JP JP2019213582A patent/JP2020063258A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012000862A8 (pt) | composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento | |
EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
BR112015008365A2 (pt) | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente | |
BRPI0820800A2 (pt) | Dispositivo médico implantável para liberação controlada de droga, e, métodos para administração de uma droga na bexiga de um paciente e para tratar a bexiga em um paciente | |
BR112012018022A2 (pt) | inibição de sinalização axl em terapia antimetastática. | |
BR112015003590A8 (pt) | Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r | |
BRPI0811845A2 (pt) | Forma de dosagem, e, métodos de preparação da forma de dosagem, e de tratamento de uma má condição em um paciente | |
BR112013013525A2 (pt) | formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central | |
IL223783B (en) | Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine | |
EA201100313A1 (ru) | Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом | |
BRPI0906850A2 (pt) | módulo terapêutico, sistema e dispositivo terapêutico para aliviar a dor e prover um efeito cicatrizante curativo, e, método para administrar alívio da dor com pelo menos um módulo terapêutico. | |
EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
BR112014014262A2 (pt) | nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas. | |
EP2142244A4 (en) | MEDICAL DEVICE FOR ADMINISTERING MEDICINE AND / OR PERFORMING PHYSICAL THERAPY | |
MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
BR112013003677A2 (pt) | uso de agente farmacologicamente ativo e forma de dosagem farmacêutica | |
BR112013011480A2 (pt) | método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer | |
BRPI1014824A2 (pt) | composição farmacêutica em forma de dose unitária e método de tratamento, prevenção ou redução da ocorrência de uma condição em um indivíduo | |
BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
HK1150390A1 (en) | A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases | |
BR112015022465A2 (pt) | método para tratamento não-tóxico para síndrome de abstinência de drogas | |
IL193094A (en) | Appalidine and other drugs used in the manufacture of a cancer treatment drug when the combination of the two gives a synergistic result |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |